{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T04:21:08Z","timestamp":1770351668808,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2003,5,1]],"date-time":"2003-05-01T00:00:00Z","timestamp":1051747200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Chest"],"published-print":{"date-parts":[[2003,5]]},"DOI":"10.1378\/chest.123.5.1441","type":"journal-article","created":{"date-parts":[[2003,6,14]],"date-time":"2003-06-14T00:09:19Z","timestamp":1055549359000},"page":"1441-1449","source":"Crossref","is-referenced-by-count":119,"title":["Long-term Treatment Benefits With Tiotropium in COPD Patients With and Without Short-term Bronchodilator Responses"],"prefix":"10.1016","volume":"123","author":[{"given":"Donald","family":"Tashkin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven","family":"Kesten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1378\/chest.123.5.1441_bib1","first-page":"S77","article-title":"Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease","volume":"152","author":"American Thoracic Society","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.123.5.1441_bib2","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1164\/ajrccm.152.3.7663792","article-title":"Standardization of spirometry: 1994 update","volume":"152","author":"American Thoracic Society","year":"1995","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.123.5.1441_bib3","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1164\/ajrccm\/147.4.1056","article-title":"Guidelines for the evaluation of impairment\/disability in patients with asthma","volume":"147","author":"American Thoracic Society\/Medical Section of the American Lung Association","year":"1993","journal-title":"Am Rev Respir Dis"},{"key":"10.1378\/chest.123.5.1441_bib4","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1164\/ajrccm.163.5.9903053","article-title":"Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease","volume":"163","author":"Rennard","year":"2001","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.123.5.1441_bib5","doi-asserted-by":"crossref","first-page":"1012","DOI":"10.1016\/S0954-6111(98)90347-X","article-title":"Early reversibility to salbutamol does not always predict bronchodilation after salmeterol in stable chronic obstructive pulmonary disease","volume":"92","author":"Cazzola","year":"1998","journal-title":"Respir Med"},{"key":"10.1378\/chest.123.5.1441_bib6","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1378\/chest.115.4.966","article-title":"The combination of ipratropium and albuterol optimizes pulmonary function reversibility testing in patients with COPD","volume":"115","author":"Dorinsky","year":"1999","journal-title":"Chest"},{"key":"10.1378\/chest.123.5.1441_bib7","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1164\/ajrccm\/146.3.555","article-title":"Acute bronchodilator trials in chronic obstructive pulmonary disease","volume":"146","author":"Nisar","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1378\/chest.123.5.1441_bib8","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1378\/chest.115.4.957","article-title":"Efficacy of salmeterol xinafoate in the treatment of COPD","volume":"115","author":"Mahler","year":"1999","journal-title":"Chest"},{"key":"10.1378\/chest.123.5.1441_bib9","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1183\/09031936.95.08081398","article-title":"Optimal assessment and management of chronic obstructive pulmonary disease (COPD): European Respiratory Society Task Force","volume":"8","author":"Siafakas","year":"1995","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.123.5.1441_bib10","series-title":"Global Initiative for Chronic Obstructive Lung Disease (GOLD), global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (executive summary)","author":"National Institutes of Health","year":"2001"},{"key":"10.1378\/chest.123.5.1441_bib11","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1183\/09031936.02.00269802","article-title":"A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease","volume":"19","author":"Casaburi","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.123.5.1441_bib12","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1164\/ajrccm.161.4.9903044","article-title":"Long-acting bronchodilation with once-daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease","volume":"161","author":"Littner","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1378\/chest.123.5.1441_bib13","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S0024-3205(98)00588-8","article-title":"Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease","volume":"64","author":"Disse","year":"1999","journal-title":"Life Sci"},{"key":"10.1378\/chest.123.5.1441_bib14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1089\/089426801316970268","article-title":"Effective delivery of particles with the HandiHaler dry powder inhalation system over a range of chronic obstructive pulmonary disease severity","volume":"14","author":"Chodosh","year":"2001","journal-title":"J Aerosol Med"},{"key":"10.1378\/chest.123.5.1441_bib15","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1378\/chest.93.1.123","article-title":"Fifteen-year interval spirometric evaluation of the Oregon predictive equations","volume":"93","author":"Morris","year":"1988","journal-title":"Chest"},{"key":"10.1378\/chest.123.5.1441_bib16","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1378\/chest.85.6.751","article-title":"The measurement of dyspnea: contents, interobserver agreement, and physiologic correlates of two new clinical indexes","volume":"85","author":"Mahler","year":"1984","journal-title":"Chest"},{"key":"10.1378\/chest.123.5.1441_bib17","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1164\/ajrccm\/145.6.1321","article-title":"A self-complete measure of health status for chronic airflow limitation: the St. George\u2019s respiratory questionnaire","volume":"145","author":"Jones","year":"1992","journal-title":"Am Rev Respir Dis"},{"key":"10.1378\/chest.123.5.1441_bib18","doi-asserted-by":"crossref","first-page":"1202","DOI":"10.1164\/ajrccm\/144.5.1202","article-title":"Lung function testing: selection of reference values and interpretative strategies","volume":"144","author":"American Thoracic Society","year":"1991","journal-title":"Am Rev Respir Dis"},{"key":"10.1378\/chest.123.5.1441_bib19","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1378\/chest.115.3.697","article-title":"Eosinophilic inflammation in the airway is related to glucocorticoid reversibility in patients with pulmonary emphysema","volume":"115","author":"Fujimoto","year":"1999","journal-title":"Chest"},{"key":"10.1378\/chest.123.5.1441_bib20","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/arrd.1986.133.1.14","article-title":"Bronchodilator response in chronic obstructive pulmonary disease","volume":"133","author":"Anthonisen","year":"1986","journal-title":"Am Rev Respir Dis"},{"key":"10.1378\/chest.123.5.1441_bib21","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1183\/09031936.93.05080975","article-title":"A comparison of six different ways of expressing the bronchodilating response in asthma and COPD: reproducibility and dependence of prebronchodilator FEV1","volume":"5","author":"Dompeling","year":"1992","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.123.5.1441_bib22","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1378\/chest.105.4.1042","article-title":"Is the short-term response to inhaled beta-adrenergic agonist sensitive or specific for distinguishing between asthma and COPD?","volume":"105","author":"Kesten","year":"1994","journal-title":"Chest"},{"key":"10.1378\/chest.123.5.1441_bib23","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1034\/j.1399-3003.1999.14d27.x","article-title":"Nonreversible airflow obstruction in life-long nonsmokers with moderate to severe asthma","volume":"14","author":"Ulrik","year":"1999","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.123.5.1441_bib24","first-page":"43","article-title":"Contribution of ipratropium bromide to the bronchodilator test in patients with chronic obstructive pulmonary disease","volume":"12","author":"Rodriguez-Carballeira","year":"1999","journal-title":"Pulm Pharmacol Ther"},{"key":"10.1378\/chest.123.5.1441_bib25","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/0007-0971(77)90120-6","article-title":"Definition of asthma for clinical trials","volume":"71","author":"Clark","year":"1977","journal-title":"Br J Dis Chest"},{"key":"10.1378\/chest.123.5.1441_bib26","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1378\/chest.117.4.1146","article-title":"Office spirometry for lung health assessment in adults: a consensus statement from the National Lung Health Education Program","volume":"117","author":"Ferguson","year":"2000","journal-title":"Chest"},{"key":"10.1378\/chest.123.5.1441_bib27","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1183\/09031936.02.00238702","article-title":"Improved health outcomes in patients with COPD during one year treatment with tiotropium","volume":"19","author":"Vincken","year":"2002","journal-title":"Eur Respir J"},{"key":"10.1378\/chest.123.5.1441_bib28","doi-asserted-by":"crossref","first-page":"1411","DOI":"10.1378\/chest.105.5.1411","article-title":"In chronic obstructive pulmonary disease, a combination of ipratropium and albuterol is more effective than either agent alone: an 85-day multicenter trial","volume":"105","author":"COMBIVENT Inhalation Aerosol Study Group","year":"1994","journal-title":"Chest"},{"key":"10.1378\/chest.123.5.1441_bib29","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1378\/chest.119.6.1661","article-title":"Salmeterol plus theophylline combination therapy in the treatment of COPD","volume":"119","author":"ZuWallack","year":"2001","journal-title":"Chest"},{"key":"10.1378\/chest.123.5.1441_bib30","series-title":"Clinical measurement of dyspnea. Mt.","first-page":"75","author":"Mahler","year":"1990"}],"container-title":["Chest"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215336746?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0012369215336746?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,12]],"date-time":"2024-12-12T22:09:52Z","timestamp":1734041392000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0012369215336746"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,5]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2003,5]]}},"alternative-id":["S0012369215336746"],"URL":"https:\/\/doi.org\/10.1378\/chest.123.5.1441","relation":{},"ISSN":["0012-3692"],"issn-type":[{"value":"0012-3692","type":"print"}],"subject":[],"published":{"date-parts":[[2003,5]]}}}